CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

AstraZeneca shares slump after $400bn BMS merger rumours

Negative
AI Analysis

Summary

AstraZeneca shares declined following reports of a potential $400bn merger with Bristol Myers Squibb that would create one of the largest global pharmaceutical companies.

Importance:7/10
Sentiment:
-0.60
M&Amergerrumorstock_movement
Related Companies

Read the original article

Published by Pharmaceutical Technology on August 3, 2026 3:03 PM

Read Original